Literature DB >> 10037168

Pharmacoeconomics of schizophrenia in the 21st century.

M A Hanson1.   

Abstract

During the next century-if not before-a variety of issues associated with mental health care in the United States need to be addressed and resolved nationwide, including securing full parity for patients with psychiatric disorders, improving the overall medical health of psychiatric patients, establishing the effectiveness as well as the efficacy of new drugs and educating health care providers about new drugs and new uses for older drugs, and using all costs to evaluate new therapeutic strategies or medications. The following discussion covers some of the major findings from studies conducted in the Commonwealth of Massachusetts, touches on some of the areas mentioned above, and is intended to serve as a springboard for exchanges among professionals in the health care community who care for psychiatric patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10037168

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  1 in total

1.  Use of conventional antipsychotics and the cost of treating schizophrenia.

Authors:  R R Lyu; J S McCombs; B M Johnstone; D N Muse
Journal:  Health Care Financ Rev       Date:  2001
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.